CARDIFF, UK, March 18, 2019 / B3C newswire / -- Cellesce and Hubrecht Organoid Technology (HUB) have today announced a licence agreement for the expansion of organoids using Cellesce’s own bioprocessing technology and HUB Organoid Technology for the scale up of breast organoids.
Cellesce and HUB have an ongoing agreement for the expansion of organoids using HUB Technology. In a new project, funded by Innovate UK, Cellesce will expand breast cancer organoids using a combination of HUB Organoid Technology and Cellesce’s own bioprocessing technology. The project aims to confirm that breast cancer organoids remain genetically and phenotypically stable and continue to faithfully recapitulate the characteristics of the tumours from which they were originally derived. The project will provide support for the scaling of organoid expansion to generate the quantities of organoids required by commercial and academic researchers in drug discovery programmes.
Cellesce Chief Executive, Dr Mark Treherne, commented: “By partnering with HUB Cellesce will be in a position to provide an integrated drug discovery solution. This will be a comprehensive package that supplies organoids at scale which will increase the impact that organoid models are having on the cancer research community.”
“HUB Organoid Technology will benefit from Cellesce’s innovative technology to expand large quantities of organoids such as breast cancer organoids.” added Dr Rob Vries, Managing Director of the HUB.
Based in Cardiff, UK, Cellesce is a biotechnology company that has developed a patented bioprocessing technology for the growing on and expansion of organoids. Cellesce aims to become a leading contract research organisation focused on the supply of standardised and well characterised cancer organoids for large-scale applications such as compound screening, especially for high throughput screening requirements, where significant quantities of reproducible batches are required.
Hubrecht Organoid Technology (HUB) is an organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. HUB exploits the pioneering work of Prof. Hans Clevers, who discovered methods to grow stem cell-derived human ‘miniorgans’ (HUB Organoids) from tissues of patients with various diseases. The organoids, which are part of the HUB biobanks, are characterized by genome sequencing, expression profiling and sensitivity to known and experimental drugs to establish a database linking genetic and transcriptional information to drug responsiveness. HUB offers licenses for its patented HUB Organoid Technology for drug-screening and access to organoids in the HUB biobanks for preclinical drug discovery and validation. In addition, HUB is performing clinical studies to validate the technology’s use as a companion diagnostic.
Dr Mark Treherne, Chief Executive
William Allbrook, Marketing Director
Dr Robert Vries, Managing Director,
Dr Bahar Ramezanpour, Head Business Development
Published by B3C newswire and shared through Newronic®